Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Boniva 150 Mg 3 Tabs By Genetech Inc.

Image 0 of Boniva 150 Mg 3 Tabs By Genetech Inc.Image 1 of Boniva 150 Mg 3 Tabs By Genetech Inc.Image 2 of Boniva 150 Mg 3 Tabs By Genetech Inc.

Boniva 150 Mg 3 Tabs By Genetech Inc.

Call for Price

Boniva 150 Mg 3 Tabs By Genetech Inc. Free Shipping. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3657137/RXB10059583/RXA318361
Size : 3
Selling UoM : EA
NDC: 00004-0186-82
UPC Barcode : 300040186826
Supplier: 0050001904 GENENTECH, INC. USA
Supplier Material : 018682
Generic Code : 058915 IBANDRONATE SODIUM ORAL TABLET 150 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  Call for Price

Product Description.:

BNVA, 150
tablet , film-coated , white , oblong oblong

Boniva is indicated for the management of postmenopausal osteoporosis.

Important Safety Information for Boniva Tablets

Boniva Tablets are contraindicated in patients with uncorrected hypocalcemia, known hypersensitivity to any component of this product, or the inability to stand or sit upright for at least 60 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy. Adequate intake of calcium and vitamin D is important in all patients. Boniva is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Boniva, like other bisphosphonates administered orally, may cause upper gastrointestinal (GI) disorders such as dysphagia, esophagitis, and esophageal or gastric ulcers. As aspirin, NSAIDs, and bisphosphonates are associated with GI irritation, caution should be exercised when using them concomitantly. Boniva Tablets should be taken at least 60 minutes before any oral medication or supplementation including calcium, antacids, or vitamins. Rarely, patients have reported severe bone, joint, and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates most cases have been in cancer patients undergoing dental procedures. The overall adverse events profile of Boniva 2.5 mg once daily was similar to that of placebo. In a one-year study comparing Boniva 150 mg once-monthly and Boniva 2.5 mg daily, the overall incidence of adverse events with the two dosing regimens was similar. The most commonly reported adverse events (��%), regardless of causality, were abdominal pain (Boniva 150 mg 7.8% vs Boniva 2.5 mg 5.3%), hypertension (6.3% vs 7.3%), dyspepsia (5.6% vs 7.1%), arthralgia (5.6% vs 3.5%), nausea (5.1% vs 4.8%), and diarrhea (5.1% vs 4.1%).

Click here for Prescribing Information